After exiting Y Combinator, we achieved $200,000 in revenue within six weeks, and by the end of the year, we reached about $1 million, showcasing our rapid growth trajectory.

I co-founded Y Combinator, the first startup accelerator, which began with a hypothesis about what people wanted, and it turned out they did want it, leading us to fund over 1,800 startups valued at over a hundred billion dollars.

Many biotech companies have raised significantly more capital through Y Combinator than they would have in traditional biotech venture settings, with over $200 million raised for these companies.

The last three batches of Y Combinator have consistently grown their revenue by 10% week on week, a feat not seen before in previous cycles.

We were accepted into Y Combinator, which was a significant milestone for us and changed the course of our company.

Despite starting Y Combinator with the goal of helping a few entrepreneurs, we never anticipated funding a thousand startups, many of which have become very successful.

The experience in the Y Combinator batch has exceeded expectations, proving to be life-changing and transformational for the founders' perspectives on their business.

Y Combinator has shifted from primarily investing in consumer startups to focusing on B2B companies, which are currently valued at approximately $170 billion.

We raised two and a half million dollars on a twelve million dollar valuation after nine months of fundraising post-Y Combinator demo day.